Trastuzumab Plus Pertuzumab Approved in EU for First-Line HER2-Positive Metastatic Breast Cancer
Jim Weiss: Make It Happen
Ziihera Plus Chemotherapy Improves Overall Survival in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
An Appeal for Solidarity, Compassion, and Support for Nepal’s Ongoing Rescue and Recovery Efforts
The Win-Win Imperative: A Global Call to Make High-Value Cancer Care Affordable
HUTCHMED Reports Positive Phase 3 SANOVO Results for Savolitinib Plus Osimertinib in EGFR-Mutated NSCLC
Pashtoon Kasi: Lessons from the NEST Phase 2 Trial in Colon Cancer
By Women, for Women: The Untold Stories at the Roots of Oncology
![Piotr Wysocki: [89Zr]Zr-girentuximab is highly sensitive and specific for clear-cell RCC imaging](https://oncodaily.com/pub/uploads/2024/09/Screenshot-2024-09-14-174634-800x448.png "Piotr Wysocki: [89Zr]Zr-girentuximab is highly sensitive and specific for clear-cell RCC imaging 9")
